AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 104 filers reported holding AKERO THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,332 | +37.9% | 27,600 | +27.8% | 0.00% | +50.0% |
Q2 2023 | $966 | +19.0% | 21,600 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $812 | +8.7% | 21,600 | +54.3% | 0.00% | 0.0% |
Q4 2022 | $747 | -99.8% | 14,000 | 0.0% | 0.00% | +100.0% |
Q3 2022 | $417,000 | +111.7% | 14,000 | +3.7% | 0.00% | – |
Q1 2022 | $197,000 | -24.5% | 13,500 | +9.8% | 0.00% | -100.0% |
Q4 2021 | $261,000 | -1.9% | 12,300 | +2.5% | 0.00% | 0.0% |
Q3 2021 | $266,000 | -12.8% | 12,000 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $305,000 | -9.8% | 12,000 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $338,000 | +12.3% | 12,000 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $301,000 | – | 12,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 5,830,203 | $168,435,000 | 13.00% |
venBio Partners LLC | 2,444,311 | $63,063,000 | 5.57% |
Versant Venture Management, LLC | 777,727 | $20,065,000 | 2.08% |
Vivo Capital, LLC | 633,426 | $16,342,000 | 0.73% |
Redmile Group, LLC | 2,322,557 | $59,922,000 | 0.73% |
Boxer Capital, LLC | 831,495 | $21,453,000 | 0.69% |
Integral Health Asset Management, LLC | 85,000 | $2,193,000 | 0.65% |
SILVERARC CAPITAL MANAGEMENT, LLC | 35,179 | $908,000 | 0.53% |
HighVista Strategies LLC | 27,739 | $716,000 | 0.46% |
Cormorant Asset Management, LP | 742,549 | $19,158,000 | 0.46% |